Despite this limitation to generalizability, the current sample may better represent those for whom future GLP-1 agonist treatment would be warranted by its efficacy for binge eating, specifically in the absence of its indications for medical conditions or obesity or its clear contraindication for patients who are medically underweight. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.